Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director | June 06, 2024 | June 07, 2024 |
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Director · Chief Executive Officer | October 31, 2025 | November 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,409,928 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 35,000 · Balance 2,409,928 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
Marker Therapeutics, Inc.
Report date October 31, 2025 · Filed November 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2035-10-31 | Direct | 250,000 |
Reported balance
After 2025-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-31 · Grant · Acquired 250,000 · Balance 250,000 F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2025 Filed Nov 4, 2025 22:03 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001755495-25-000003 · primary_doc.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-10-31 F1 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:17 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001104659-25-014315 · tm256716-4_4seq1.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-02-12 F1 · shares: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025. F1 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070597 · ownership.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,409,928 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029099 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,374,928 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-23-028846 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-10 F1 · derivative.exercise_date: This option vests in equal annual installments on May 10, 2024, May 10, 2025, May 10, 2026 and May 10, 2027 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:49 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 46,487 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-014158 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,487 Underlying: Common Stock · 46,487 shares Expires 2033-02-27 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:23 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0000899243-22-018820 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 01:04 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | Tax withholdingCommon Stock | 33,465 | $0.48 | $16,223.83 |
DisclosureSEC source: 0001209191-22-021395 · doc4.xml · nonDerivative · entry 2 Vera Juan · CIK 0001755495 · Director · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671,845 F2 · shares: Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 01:04 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 140,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021395 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,705,310 F1 · shares: Represents a restricted stock unit ("RSU") award. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:12 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-22-011787 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:47 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0000899243-21-020862 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-24 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:38 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | PurchaseCommon Stock | 571,428 | $1.75 | $999,999.00 |
DisclosureSEC source: 0001209191-21-021773 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,564,487 Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 7,546 | $38.63 | $291,517.83 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 9 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,339,928 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.50 to $38.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 7,142 | $38.22 | $272,953.67 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 8 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,347,474 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.50 to $38.495. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,300 | $37.01 | $48,113.52 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 7 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,354,616 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.50 to $37.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,803 | $39.10 | $70,500.00 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 6 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,355,916 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.84 to $39.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 9,001 | $38.30 | $344,707.70 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 5 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,357,719 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.84 to $38.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,190 | $37.28 | $156,188.54 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 4 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,366,720 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.84 to $37.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 700 | $39.53 | $27,671.00 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 3 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370,910 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.515 to $39.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 20,584 | $38.73 | $797,265.66 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 2 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,371,610 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.49 to $39.478. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 11,570 | $38.28 | $442,841.75 |
DisclosureSEC source: 0001209191-21-017536 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,392,194 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.49 to $38.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 600 | $40.97 | $24,582.48 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 8 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,403,764 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.77 to $41.225. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,300 | $40.13 | $92,293.94 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 7 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,404,364 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.76 to $40.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,825 | $39.11 | $188,691.76 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 6 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,406,664 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.75 to $39.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,125 | $38.33 | $43,116.08 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 5 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,411,489 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.74 to $38.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 380 | $43.40 | $16,492.80 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 4 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412,614 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.34 to $43.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 11,050 | $42.80 | $472,906.85 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 3 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412,994 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.31 to $43.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,891 | $41.58 | $120,214.72 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 2 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424,044 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.25 to $42.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 13,233 | $41.79 | $553,011.04 |
DisclosureSEC source: 0001209191-21-013486 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,426,935 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.34 to $42.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 13:41 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,710 | $41.49 | $153,923.08 |
DisclosureSEC source: 0000899243-21-007331 · doc4.xml · nonDerivative · entry 3 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,440,168 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.04 to $41.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 13:41 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,032 | $40.44 | $163,069.40 |
DisclosureSEC source: 0000899243-21-007331 · doc4.xml · nonDerivative · entry 2 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,443,878 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.93 to $40.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 13:41 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,200 | $39.48 | $47,375.88 |
DisclosureSEC source: 0000899243-21-007331 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,447,910 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,060 | $41.26 | $167,506.67 |
DisclosureSEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 5 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,449,110 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.73 to $41.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,400 | $40.00 | $56,002.66 |
DisclosureSEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 4 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,453,170 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.54 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,000 | $38.71 | $77,420.60 |
DisclosureSEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 3 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454,570 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.21 to $39.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 966 | $42.53 | $41,081.37 |
DisclosureSEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 2 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,456,570 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.25 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 9,434 | $41.79 | $394,283.65 |
DisclosureSEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,457,536 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.20 to $42.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:39 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001209191-21-010312 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 10:21 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 3,631,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021610 · doc4.xml · derivative · entry 2 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,436,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 10:21 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionCommon Stock | 2,436,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021610 · doc4.xml · nonDerivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,466,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:38 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020917 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-07-29 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:43 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 113,400 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018548 · doc4.xml · derivative · entry 2 Vera Juan · CIK 0001755495 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,400 Underlying: Common Stock · 113,400 shares Expires 2030-03-10 F2 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:43 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 26,600 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018548 · doc4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: Common Stock · 26,600 shares Expires 2030-03-10 F1 · derivative.exercise_date: Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 21:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001144204-18-054993 · tv505272_form4.xml · derivative · entry 1 Vera Juan · CIK 0001755495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-10-19 F1 · security: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, that were granted in connection with entering into a consulting agreement with the Company to serve as the Company's Chief Development Officer. One quarter of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal monthly installments over a three year period upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018. F1 · derivative.exercise_date: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, that were granted in connection with entering into a consulting agreement with the Company to serve as the Company's Chief Development Officer. One quarter of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal monthly installments over a three year period upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.